Non-Hodgkin Lymphoma Therapeutics Market By Type of Therapy (Chemotherapy, Radiation Therapy, Targeted Therapy, Other Types of Therapies By Cell Type (B-cell Lymphomas, T-cell Lymphoma)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Key Highlights of the Report

The global non-hodgkin lymphoma therapeutics market is segmented by type of therapy, cell type, and region. Radiation therapy category is the most popular, while chemotherapy is the two primary type of therapy segment. B-cell lymphomas category accounted for a higher share of cell type, with North America leading the market growth.

The global non-hodgkin lymphoma therapeutics market has several drivers, including the increasing incidence of non-hodgkin lymphoma, the expansion of potential pipeline medications, the high rate of diagnostics, and the susceptible pediatric population are the main drivers of the worldwide non-hodgkin lymphoma market. The need for innovative ovarian cancer medications is thought to be positively influenced by the variety of therapy options and family history of the disease. COVID-19 significantly impacted the market growth. However, the market also faces significant challenges, such as the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards.

Nonetheless, the global non-hodgkin lymphoma therapeutics market offers significant growth opportunities as prevalence rises, more clinical trials are being conducted, and many more medications are being developed.

Market Overview

The global non-hodgkin lymphoma therapeutics market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 8.80% between 2023 and 2030. The market was valued at USD 8.5 billion in 2022 and is expected to reach USD 15.34 billion in 2030.

What Are The Main Drivers Of The Global Non-Hodgkin Lymphoma Therapeutics Market?

The global non-hodgkin lymphoma therapeutics market is driven by the increasing incidence of non-hodgkin lymphoma, the expansion of potential pipeline medications, the high rate of diagnostics, and the susceptible pediatric population are the main drivers of the worldwide non-hodgkin lymphoma market. The need for innovative ovarian cancer medications is thought to be positively influenced by the variety of therapy options and family history of the disease. COVID-19 significantly impacted the market growth.

What Are The Major Challenges Faced By The Global Non-Hodgkin Lymphoma Therapeutics Market?

The global non-hodgkin lymphoma therapeutics market also faces several challenges, including the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards.

What Are The Growth Opportunities In The Global Non-Hodgkin Lymphoma Therapeutics Market?

The global non-hodgkin lymphoma therapeutics market offers significant growth opportunities as prevalence is rising, more clinical trials are being conducted, and many more medications are being developed.

Executive Summary

Overview of the Global Non-hodgkin lymphoma therapeutics Market

The global non-hodgkin lymphoma therapeutics market has been steadily growing in recent years, driven by recent approvals, the robust pipeline, the rise in the elderly population, and unique drug designations. The industry is distinguished by a broad spectrum of therapy and cell types that appeal to various consumer preferences.

Market Definition

The phrase “lymphoma therapeutics” describes a range of medical techniques and actions used to treat lymphoma, a type of cancer that affects the lymphatic system, a part of the body’s immune system. The main objectives of lymphoma treatments are to eliminate malignant cells, stop the disease from worsening, and enhance patients’ quality of life. Lymphoma can be treated in various ways, including chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplantation. The type and stage of the lymphoma, as well as other elements like the patient’s general health and medical background, will determine the best course of treatment. Therapeutics for lymphoma are designed to bring about long-term remission and improve the prognosis for lymphoma patients.

Market Insights

• The global demand for non-hodgkin lymphoma therapeutics was valued at USD 8.5 Billion in 2022 and is expected to reach USD 15.34 Billion in 2030, growing at a CAGR of 8.80% between 2023 and 2030.
• Radiation therapy is the leading segment by type of therapy and held over 43% share in terms of value in 2022, while the chemotherapy segment is likely to exhibit the fastest CAGR during the forecast period.
• The B-cell lymphomas segment governs the global demand for non-hodgkin lymphoma therapeutics, holding a massive share of over 80% in 2022, and is expected to grow at a rapid CAGR.
• North America is fueling the growth of the non-hodgkin lymphoma therapeutics industry with over one-third share in 2022, while Asia Pacific and Europe collectively account for just under 50% share in 2022. Europe held over 22% share in 2022.
• The high prevalence and awareness of all types of cancer, including several blood malignancies like non-hodgkin’s lymphoma, contributed to North America’s supremacy in the global market. At the same time, the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards; the major market restraints are the main restraints.
• As prevalence is rising, more clinical trials are being conducted, and many more medications are being developed, which are the major opportunities in the market.

Segmentation by Type of Therapy

• Radiation therapy is the leading segment by type of therapy and held over 43% share in terms of value in 2022.
• The chemotherapy segment will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Cell Type

• The B-cell lymphomas segment governs the demand for non-hodgkin lymphoma therapeutics in the world, holding a massive share of over 80% in 2022, and is also expected to grow at a rapid CAGR.
• The T-cell lymphoma segment contributes to the rest of the demand for non-hodgkin lymphoma therapeutics.

Segmentation by Region

• North America is fueling the growth of the non-hodgkin lymphoma therapeutics industry with over one-third share in 2022.
• Asia Pacific and Europe collectively account for just under 50% share in 2022, with Europe holding over 22% share in the same year.
• The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for non-hodgkin lymphoma therapeutics.

The increasing demand for non-hodgkin lymphoma therapeutics can be attributed to the growing child population and the benefits offered by non-hodgkin lymphoma therapeutics. However, the market is restrained by the high cost of NHL medications and the significant side effects related to them.

The United States is one of the largest markets for non-hodgkin lymphoma therapeutics in North America, with a significant market share. Due to an increase in lymphoma prevalence, advancements in lymphoma therapeutics, including targeted therapies and immunotherapies, and an increase in the number of new product releases by important market participants in this region. For example, the U.S. FDA approved Jaypirca (pirtobrutinib) in January 2023 as the first and only non-covalent (reversible) Bruton’s tyrosine kinase (BTK) BTK inhibitor for adult patients with relapsed or refractory mantle cell lymphoma following at least two lines of systemic therapy, including a (BTK) inhibitor.

China is also a major market for non-hodgkin lymphoma therapeutics in Asia, with a significant market share, due to a growth in the number of people who have lymphoma and the number of measures being taken in the R&D sector to create cutting-edge medicines for the disease. A rise in the elderly population in developing nations like India, China, Japan, and South Korea and increased awareness of the available lymphoma treatment choices are other factors driving the market’s expansion.

Overall, the increasing demand for non-hodgkin lymphoma therapeutics can be attributed to the market growth due to increased pharmaceutical companies’ R&D spending and rising healthcare costs in industrialized nations like the United States and Canada.

While the non-hodgkin lymphoma therapeutics market is growing, it faces challenges from the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards are the major market restraints. Manufacturers are innovating and forming partnerships to stay competitive.

Non-Hodgkin Lymphomas are More Common, Which will Boost the Market.

The present trends of greater prevalence of nearly all types of cancers, including numerous types of non-hodgkin lymphomas, are the main drivers of this market for non-hodgkin lymphoma treatment. Non-Hodgkin lymphomas can vary greatly in their aggressiveness, so a precise treatment strategy is necessary. Effective and cutting-edge non-hodgkin lymphoma therapy items frequently lead to better and more favorable clinical outcomes. Many of these malignancies frequently don’t show signs until the disease progresses. At this point, strong and effective therapies are required for improved clinical results. During the projected period, these factors are anticipated to support the growth of the non-hodgkin lymphoma therapy market.

An important motivator is a desire for better clinical and therapeutic outcomes for patients with non-hodgkin lymphomas where the illness has relapsed or become refractory. A different course of treatment is frequently needed for these types of NHL, which increases the demand for highly advanced targeted medicines such as targeted therapies and immunotherapies.

Higher Adoption of Non-Hodgkin Lymphoma Treatment Products Due to High Cure Rates

One of the main driving forces is the continued and expanded R&D activity in creating effective therapies for various non-hodgkin lymphomas. Many NHLs are now being identified early thanks to the development of more sophisticated diagnostic tools, which improve patient prognosis. The market for non-hodgkin lymphoma treatments is anticipated to rise due to positive cure rates. A better prognosis for an illness increases the likelihood that people will use improved treatment, which further increases the income generated by the global market. This is since effective diagnostic methods, great cure rates, and modern therapies frequently go hand in hand for better treatment outcomes.

The Adoption of Advanced Therapeutics is Limited by the High Cost of Approved Therapeutics in Emerging Economies

Numerous blood malignancies, including lymphomas, have sharply increased prevalence rates. These trends have also been observed in several developing nations. The high prices associated with some medicines, such as immunotherapies, are the main obstacles to expanding the non-hodgkin lymphoma therapy industry. This substantially limits the number of patients receiving complex and cutting-edge treatment; most lymphoma patients go untreated. Patients frequently cannot embrace these cutting-edge treatment choices, which frequently produce better clinical outcomes, due to the lack of suitable payment plans and special considerations by the regional governments.

The worldwide NHL therapies market faces significant growth barriers due to limited access to therapy.

Limited access to treatment for most patients worldwide is one of the biggest issues facing the market. Nearly all approved medications for treating non-hodgkin lymphoma are available in most of North America and Europe. However, developing and undeveloped economies have few therapeutic alternatives for treating diseases. Despite the high occurrence of different blood malignancies, such as non-hodgkin lymphoma, in these nations, patients find it challenging to receive treatment on time due to the poor availability of treatment alternatives. Due in part to the lack of patient assistance programmes, the lack of advanced healthcare infrastructure, and the high cost of medicines, a sizeable segment of the patient population in these countries cannot afford treatment.

Non-Hodgkin lymphoma incidence rising

The American Cancer Society estimates about 80,470 new cases of non-hodgkin lymphoma per year. The age ranges between 80 and 84 for females, and 85 to 89 for males is when the highest rates are observed. Some of these tumors are incredibly aggressive. Better clinical outcomes are becoming increasingly important to properly treat patients. As a result, it stimulates market expansion.

Increased awareness of healthcare

People are becoming more health conscious, so medications are expected to help the market grow. The market is anticipated to be stimulated simultaneously by novel drug introductions to treat ovarian cancer. Many researchers are funding the development of pharmaceuticals that will benefit the market. This expands the market’s window of opportunity.

Competitive Landscape

Key Players

The global non-hodgkin lymphoma therapeutics market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann La-Roche Ltd
• GlaxoSmithKline PLC
• Seattle Genetics
• Teva Pharmaceuticals
• Takeda Pharmaceutical Company Limited
• Spectrum Pharmaceuticals Inc.
• Janssen Pharmaceuticals Inc.

These companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions to stay ahead in the market. The major players in the global non-hodgkin lymphoma therapeutics market constantly strive to stay ahead by introducing new products and innovations.

An innovative gene therapy medicine called Breyanzi (lisocabtagene maraleucel) received commercial approval in the European Union in January 2022 to treat adult patients with diffuse large B-cell lymphoma.

The Food and Drug Administration (FDA) granted C-CAR039 approval in January 2022 for treating patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). C-CAR039 is a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, and it has been given both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation.

According to a Bristol Myers Squibb Company, Breyanzi, a CAR-T cell therapy, has been approved by the FDA for the treatment of large B-cell lymphoma in patients who have relapsed or who have not responded to prior therapies following the two other kinds of systematic treatments.

Summary of Key Findings

• This type of lymphoma therapy market is experiencing considerable demand due to the significant prevalence of numerous non-hodgkin lymphoma subtypes, recent product approvals, and promising pipeline candidates from several market participants. Driving market growth
• Market segmented by type of therapy, cell type, and region.
• Radiation therapy is the most popular, with chemotherapy as the primary user segment.
• B-cell lymphomas are the most common cell types.
• North America is leading market growth; the market is highly competitive with key players including AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Seattle Genetics, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., and Janssen Pharmaceuticals Inc.

Future Outlook

• Positive outlook for the global non-hodgkin lymphoma therapeutics market with significant growth potential in the North American region
• As prevalence is rising, more clinical trials are being conducted, and many more medications are being developed. To drive growth
• Challenges from the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards are the major market restraints.
• Key players to focus on product innovation, expanding market reach and maintaining competitive pricing to stay ahead in the market.

Segmentation

• By Type of Therapy
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Other Types of Therapies
• By Cell Type
  • B-cell Lymphomas
  • T-cell Lymphoma
• By Region
• North America
  • The US.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • The U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa